| Literature DB >> 31195642 |
Sandra Pina1,2, Viviana P Ribeiro3,4, Catarina F Marques5,6, F Raquel Maia7,8,9, Tiago H Silva10,11, Rui L Reis12,13,14, J Miguel Oliveira15,16,17.
Abstract
During the past two decades, tissue engineering and the regenerative medicine field have invested in the regeneration and reconstruction of pathologically altered tissues, such as cartilage, bone, skin, heart valves, nerves and tendons, and many others. The 3D structured scaffolds and hydrogels alone or combined with bioactive molecules or genes and cells are able to guide the development of functional engineered tissues, and provide mechanical support during in vivo implantation. Naturally derived and synthetic polymers, bioresorbable inorganic materials, and respective hybrids, and decellularized tissue have been considered as scaffolding biomaterials, owing to their boosted structural, mechanical, and biological properties. A diversity of biomaterials, current treatment strategies, and emergent technologies used for 3D scaffolds and hydrogel processing, and the tissue-specific considerations for scaffolding for Tissue engineering (TE) purposes are herein highlighted and discussed in depth. The newest procedures focusing on the 3D behavior and multi-cellular interactions of native tissues for further use for in vitro model processing are also outlined. Completed and ongoing preclinical research trials for TE applications using scaffolds and hydrogels, challenges, and future prospects of research in the regenerative medicine field are also presented.Entities:
Keywords: biomaterials; biopolymers; bioprinting; hydrogels; inorganic materials; porous structures; regenerative medicine; scaffolds; tissue engineering
Year: 2019 PMID: 31195642 PMCID: PMC6600968 DOI: 10.3390/ma12111824
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Some biopolymers derived from renewable resources and respective chemical structures: silk fibroin, alginate, and chitin.
Figure 2(A) Alumina/zirconia bioceramics for hip joint prosthesis and dentistry [67,68]; (B) (i) Bioactive glass-ceramics for dental applications and (ii) robocast glass scaffolds produced by scientists at Missouri University of Science and Technology [69,70]; (C) CaPs-based bone graft materials, such as porous blocks, powders and granules, hydroxyapatite (HAp) coating on a femoral metal stem, and self-setting CPC pastes that can be injected into the bone defect. Adapted from previous studies [71,72] with permission. (D) Images of marine organisms, namely shells, corals, sponges, and nacres, and microstructure image of the nacre structure, evidencing the plate-like aragonite crystals (i) and glass sponge (ii). Reprinted from a previous study [50] with permission.
Figure 3(A) Scaffolds of marine collagen: marine biopatite particles composite. Representative images of 12.5% 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride/N-Hydroxysuccinimide (EDC/NHS) crosslinked scaffolds obtained by microcomputed tomography (micro-CT). (B) X-ray 2D projection and respective (C) 3D reconstruction of acquired structures, in which the first column shows a reconstruction of both polymeric and ceramic phases, and the second column shows only the ceramic phase. Homogeneous distribution of the materials is observed, according to a color scale: blue = soft material (marine collagen); brown = hard material (marine biopatite particles). Adapted from a previous study [105] with permission.
Figure 4Scanning electron micrographs of silk fibroin (SF), SF/tricalcium phosphate (TCP), and SF/ionic-doped TCP scaffolds before (A) and after 15 days of mineralization (B). Viability and proliferation of the scaffolds seeded with human adipose-derived stem cells (hASCs): Alamar blue assay of hASCs cultured for 14 days (left), and DNA quantification at different time points (right) (C); *significant differences compared with SF and SF/Mn-doped TCP (MnTCP) and with SF/MnTCP and SF/Sr-doped TCP (SrTCP) (p < 0.05); **significant differences compared between SF and SF/TCP (p < 0.005); ***significant differences compared between SF at 3 d and the different compositions at 28 d (p < 0.0005); ****significant differences compared between with SF and SF/SrTCP and SF/ZnTCP (p < 0.0001). Adapted from a previous study [64] with permission.
Figure 5(A) Scanning electron micrographs showing morphological aspects of S1.65 (Ca/P = 1.65) and S1.59 (Ca/P = 1.59) scaffolds with and without levofloxacin: (a–d) lateral views; (e,f) top-views; (g) filament detail, (h) pore detail; (B) 2D (top plane and cross-section views) and 3D images of S1.65 scaffolds with and without drug (levofloxacin) obtained through Metrology CT and 3D reconstruction of the scaffolds mapped with color-coded for the internal porosity of filaments. (C) The 3D and 2D views of overlapped S1.65 and S1.65- levofloxacin (LEV) mapped with color-coding. Adapted from a previous study [119] with permission.
The most recent studies of cellular and acellular 3D porous scaffold strategies for TE purposes.
| Technology | Materials | Cells/Growth Factors | Outcomes | Application | Ref. |
|---|---|---|---|---|---|
| Freezing and lyophilization | Collagen (Col)/carbon nanotube (CNT)/chitosan (CS)/hydroxyapatite (HAp) | - | Increased hydrophilicity from 87.8° to 76.7° and improved mechanical properties of the composite scaffolds compared to Col (211 kPa), CS (284 kPa), Col/CNT (311 kPa), and Col/CNT/CS (524 kPa) scaffolds | Bone tissue engineering | [ |
| Na-alginate /hydroxyethylcellulose /HAp | - | After loading with Hap, the mechanical properties of the scaffolds increased deformation energy and rigidity gradient (19.44 ± 0.85 Pa), with bioactivity and biocompatibility in vitro and in vivo (implanted in femur of adult male Wistar rats for 6 weeks) | [ | ||
| Collagen from shark skin/ CaPs from shark teeth | Saos-2 cells seeding | Use of EDC/NHS crosslinking increased the attachment and proliferation of osteoblast-like cells | [ | ||
| Silk fibroin and β-tricalcium phosphate (TCP) | Human adipose stem cells (hASCs) seeded on the scaffolds | Highly interconnected macroporosity.; significant responses of hASCs proliferation and differentiation when varying the ionic dopants in the scaffolds | [ | ||
| Collagen and denatured collagen (DCol) | Rabbit chondrocytes seeding | Adhesion, proliferation, and re-differentiation of chondrocytes by Col scaffolds with triple helix and the regeneration of cartilage defects, compared with the DCol scaffolds | Cartilage tissue | [ | |
| PLLA, PCL, and collagen type I | Adipose tissue-derived mesenchymal stem cells seeding | Mechanically stronger mesh support, provided by PCL-PLLA and cell adhesion, and tissue formation promoted by the collagen type I microsponges | Skin | [ | |
| Silk fibroin | - | Elastic modules of the scaffolds between 100 and 900 kPa | n.d. | [ | |
| Decellularized extracellular matrix (dECM)/gelatin/chitosan | rat BMSCs seeding | Enhanced elastic modulus, no cytotoxicity, and enhanced proliferation | Meniscus tissue | [ | |
| bovine small intestinal submucosa (bSIS) layers/HAp microparticles/PCL | rat BMSCs seeding | Enhanced cell proliferation and osteoblastic differentiation within 21 days. Maximum strength similar in cell-laden scaffolds and cell-free scaffolds in wet conditions. | Bone | [ | |
| Robocasting | Biphasic CaP doped with Sr and Ag | MG-63 cells | Different pore sizes with compressive strengths comparable to cancellous bone. Sr and Ag improved the mechanical strength and cell proliferation and granted good antimicrobial activity against | Bone tissue engineering | [ |
| Biphasic CaP and chitosan | hDNFs (human dermal neonatal fibroblasts) | Produced levofloxacin loaded scaffolds without the sintering step. The antibiotic was not degraded during the fabrication process and its bactericidal efficacy was preserved | [ | ||
| 3D bioprinting | PCL and bioactive borate glass | hASCs-laden | Controlled release of bioactive glass; more than 60% viable hASCs on the scaffolds after 1 week of incubation. | Bone tissue engineering | [ |
| Polycaprolactone (PCL) | Saos-2 cells seeding | The non-orthogonal structures showed higher | [ | ||
| Alginate/alginate-sulfate | MC3T3-E1 cells/BMP-2 | Alginate/alginate sulfate bioinks allowed good 3D cell printing. Improvement of the release of BMP-2 was achieved using alginate sulfate. Proliferation and differentiation of the printed osteoblasts were enhanced | [ | ||
| GelMA and methacrylated hyaluronic acid (HA) modified with HAp | hASCs | Positive effects on bone matrix production and remodelling | [ | ||
| Collagen/dECM/silk fibroin (SF) | MC3T3-E1 cells | High compressive modulus mainly due to the methanol-treated SF; high cellular activities in in vitro tests using MC3T3-E1 cells, induced by Collagen and dECM. | [ | ||
| α-TCP/collagen | MC3T3-E1 cells | The scaffold showed good mechanical properties and cellular activities | [ | ||
| collagen type I/agarose with sodium alginate | Primary chondrocytes | Addition of collagen or agarose had an impact on gelling behavior and improving mechanical strength. The collagen facilitated cell adhesion, accelerated cell proliferation, and enhanced the expression of cartilage-specific genes, ( | [ | ||
| Fibrin and wollastonite | Loaded with rabbit BMSCs | Possible extensive regeneration of both cartilage and subchondral bone induced by in vivo transplantation of the scaffolds | Osteochondral tissue | [ | |
| Collagen | MC3T3-E1 | Cell-laden scaffold using tannic acid for crosslinking process. TA crosslinking increased mechanical properties and high cell viability | n.d. | [ | |
| CS/PCL | dECM coating/WJMSCs seeding | Improved osteogenic differentiation in vitro and bone regenerative potential in vivo | Bone | [ | |
| PCL/β-TCP | dECM coating/MC3T3-E1 seeding | Improved osteogenic differentiation in vitro and bone regenerative potential in vivo | Bone | [ | |
| Laser sintering technique | PCL and HAp | - | Subchondral bone regeneration and articular cartilage formation in a rabbit model | Osteochondral tissue | [ |
| Sol-gel method combined with 3D plotting | HAp/chitosan/silica | Mouse BMSCs seeding | Compressive strength comparable to the human trabecular bone | Bone regeneration | [ |
| BG obtained by sol-gel method | Zein/bioactive glass (BG) | MG-63 cells seeding | Ag-doped BG scaffolds showed antibacterial properties. | [ | |
| Electrospinning combined with electro-spraying | PCL/HAp | Murine embryonic cell seeding | High capacity to guide the migration of differentiated bone cells throughout the cavities and the ridge of the scaffolds | [ | |
| PCL/gelatin and multi-walled carbon nanotubes (MWNTs) | Adult rabbit chondrocytes seeding | Increased hydrophilicity and tensile strength, and higher bioactivity and slower degradation rate due to presence of MWNTs; | Cartilage tissue | [ | |
| Electrospinning | Graphene-incorporated electrospun PCL/gelatin | PC12 cells | 99% antibacterial properties against gram-positive and gram-negative bacteria. Good cell attachment and proliferation | Nerve tissue engineering | [ |
| PCL/collagen | Human endometrial stem cells seeding | Higher wettability, attachment, and proliferation rates of hEnSCs on the PCL/collagen scaffold | Skin | [ | |
| Polyhydroxybutyrate-co-hydroxyvaletare (PHBV) containing bredigite | - | Bredigite nanoparticles increased the mechanical properties, biodegradability, and bioactivity of the scaffolds | Bone tissue | [ | |
| PLLA/β-TCP | hMSCs seeding | Enhanced water uptake ability, in vitro bio-mineralization, and bioactivity promoted by the incorporation of β-TCP | Bone | [ | |
| PCL/Silk fibroin (SF) | Human fibroblast seeding | Good tensile strength, elasticity, and increased degradation rate, as well enhanced cell proliferation, with the presence of SF | n.d. | [ | |
| Electrospinning combined with 3D bioprinting | PCL | Laden with L929 mouse fibroblasts | Multi-layered structures—3D scaffolds—with loosely packed nanofibers, with better surface wettability (when compared to the 2D scaffolds) | n.d. | [ |
| Phase separation process | Cartilage ECM-derived/PLGA-β-TCP-collagen type I | BMSCs seeding | Enhanced OC regeneration. Chondro and osteogenic-induced BMSCs with independent environments | Osteochondral tissue | [ |
Note: n.d.: not defined; BMSCs: bone marrow stem cells; bSIS: bovine small intestinal submucosa; ECM: extracellular matrix; HA: hyaluronic acid; hMSCs: human mesenchymal stem cells; hASCs: human adipose stem cells; HAp: hydroxyapatite; PCL: polycaprolactone; PLLA: poly-L-lactic acid; SF: silk fibroin; TCP: tricalcium phosphate.
Figure 6Sonication-induced silk fibroin hydrogel preparation. (a) Ultra-sonication procedure used for aqueous silk solution transformation into a solid silk hydrogel. (b) Schematic illustration of the mechanism of silk sol-gel transition due to physical crosslinking and β-sheet aggregate formation after ultra-sonication. (c) Injectable properties of the silk hydrogels. (d) Silk hydrogel being injected into rabbit maxillary sinus cavity. (e) Illustration of the elevated sinus in a sagittal plane being filled by the injected silk hydrogel. Reprinted from a previous study [179] with permission.
Figure 7Silk fibroin bioinks and 3D printing of hydrogel-based scaffolds. (a) Schematic illustration of silk being extruded by a spider. (b) (i–iii) Rheological properties and (iv) adhesion measurements of the 3D printed hydrogels. (c) Extruded horseradish peroxidase (HRP)-crosslinked SF bioinks. (d) HRP-crosslinked SF scaffolds in the (i,iii,v) amorphous state and (ii,iv,vi) β-sheet crystalline conformation after freeze-drying and ethanol treatment. Reprinted from a previous study [192] with permission.
Figure 8The 3D bioprinting of an aortic valve conduit. (A) The 3D reconstruction of an aortic valve model. The green color indicates valve root and the red color indicates valve leaflets. Schematic illustration of the 3D bioprinting process using alginate and gelatin as bioinks encapsulated with (B) sinus smooth muscle cells (SMCs) and (C) aortic valve leaflet interstitial cells (VIC) cells. (D) Fluorescent image of two 3D bioprinted layers representing an aortic valve conduit. (E) Macroscopic image of a 3D bioprinted aortic valve conduit. Reprinted from a previous study [196] with permission.
Figure 9Structural characterization of gradient-induced 3D hydrogels. (A) The 3D reconstructions of: (i) random and (ii) linear porous architectures (isotropic and anisotropic). Red color represents methacrylated gelatin (GelMA)-methacrylated gellan gum (MAGG) blended polymers and blue color represents the hydroxyapatite (HAp) (Scale bar = 0.5 mm). Coronal and transaxial sections of the bilayered phased structures are represented, showing the continuous interface created throughout the matrices. The ceramic phase distribution is shown in purple inside the structure’s volume (Scale bar = 1 mm). (B) Quantification profiles of (i) HAp distribution, (ii) porosity percentage, and (iii) mean pore size traced for isotropic and anisotropic structures with linear and random pore distribution. (iv) Anisotropic degree assessed for each porous architecture, showing higher values on the linear porous anisotropic structures. Data of anisotropic degree was represented as mean ± SD, ranging from 0 (isotropic) to 1 (anisotropic) (P-value = 0.05, N = 3). Reprinted from a previous study [205] with permission.
Technologies and crosslinking methods for producing innovative hydrogel-based matrices for TE applications.
| Technology | Materials | Crosslinking Method | Outcomes | Application | Ref. |
|---|---|---|---|---|---|
| Injectable hydrogels | Carboxymethyl chitosan and alginate integrated with HAp nanoparticles and calcium carbonate microspheres (CMs) | Chemical crosslinking between amino and aldehyde groups of carboxymethyl chitosan (CMCS) and oxidized alginate (OAlg) | Controlled gelation time, morphology, mechanical properties, swelling ratio, and in vitro degradation by varying HAp and CMs contents; sustained drug release and antibiotic activity against bacteria | Bone tissue engineering and drug delivery | [ |
| Poly(ethylene glycol)-N-hydroxysuccinimide (PEG-NHS) | Physical crosslinking using gelatin functionalized with norbornene groups (GelNB) and crosslinked with thiol-functionalized poly(ethylene glycol) (PEGdiSH) using a LAP initiator | Cell-laden ability inside the microgels formed as 3D constructs; human BMSC viability and function preservation within the structures; upregulation of chondrogenic activity and glycosaminoglycans (GAGs) formation encouraged by the assembled microgels | Articular cartilage regeneration | [ | |
| Methacrylated decellularized cartilage hydrogel (MeSDCC) with HAp nanofibers (HAPnf), or bioglass (BG) | Photo-crosslinking | Increased mechanical stiffness and minimal bone regeneration in vivo | Bone regeneration | [ | |
| 3D printing | Alginate (AL), Methylcellulose (MC), Halloysite Nanotube (HNT), and Polyvinylidene Fluoride (PVDF) | Chemical crosslinking using calcium chloride (CaCl2) after printing | High water content and good miscibility in the printed structures; chondrocyte viability after 4 days of culture increased by the presence of PVDF | Cartilage applications | [ |
| Sodium alginate (SA) and gelatin (Gel) | Chemical crosslinking induced after printing by soaking in CaCl2 and glutaraldehyde | The hydrogels showed high transparency and excellent fluidic properties; interconnected porous formation after 3D architecting according to pre-established operating parameters; 3D printed architectures allowed chondrocyte viability and proliferation with efficient distribution within the porous structures | Cartilage repair | [ | |
| Ultrapure alginate and methylcellulose (Alg/MC) | Chemical crosslinking by Alg/MC blending | Successful encapsulation of pancreatic islets in hydrogels; good diffusion of glucose and insulin within the structures, with the embedded islets continuously producing insulin and glucagon, while still reacting to glucose stimulation | Pancreatic islets transplantation | [ | |
| Polycaprolactone (PCL)/β-tricalcium phosphate (TCP)/bone decellularized ECM (dECM) | No crosslinking | The scaffolds compressive modulus ranged from 31.3 to 39.9 MPa, having excellent bone regeneration efficacy in vitro and in vivo | Bone tissue | [ | |
| Freeze-drying | Silk fibroin (SF) and sodium alginate (SA) | Ionic crosslinking utilizing Ca2+ from calcium silicate (CS) to simultaneously crosslink SF and SA | CS inside the porous SF/CS/SA hydrogel-based structures remarkably enhanced hydrophilicity, degradation, compression resistance, bioactivity and pH of structures; the presence of CS stimulated BMSCs proliferation and ALP activity at certain concentrations | Bone tissue engineering | [ |
| Gelatin (Gel) and polycaprolactone−polyethylene glycol (PCEC) | Chemical crosslinking of Gel solution with glutaraldehyde, incorporation PCEC nanoparticles added to the Gel solution | Gel porous hydrogels incorporating PCEC nanoparticles loaded with TGF-β presented a sustained release of the growth factor and positively affected structures porosity; nanocomposite hydrogels cultured with h-AD-MSCs expressed chondrogenic-related markers with potential for chondrocytes differentiation | Cartilage tissue engineering | [ | |
| Salt-leaching | Poly(ethylene glycol) (PEG) and sodium chloride (NaCl) | Physical crosslinking of functionalized PEG solution induced by a photoinitiator and irradiated with UV light; NaCl particles added to PEG precursor solution for porosity inducement | Microporous PEG-based hydrogels supported low blood glucose levels at earlier times and provided the restoration of normoglycemia | Pancreatic islets transplantation | [ |
| Poly(lactide-co-glycolide) (PLGA), magnesium hydroxide, and renal dECM | No crosslinking | Magnesium hydroxide and dECM alleviated the inflammatory response and activated cell morphogenetic behaviors, influencing cell attachment and differentiation; the scaffold promoted the reconstruction of glomerular structure in renal tissue, contributing to the full recovery of the nephrectomized kidney | Kidney tissue | [ |
Note: ALP: alkaline phosphatase; BMSCs: bone marrow stem cells; h-AD-MSCs: human adipose-derived mesenchymal stem cells; HAp: hydroxyapatite.
Overview of the complete and ongoing clinical trials, in the last 5 years, using scaffolds and hydrogel strategies for tissue engineering and regeneration. Information obtained from https://clinicaltrials.gov/.
| ClinicalTrials.Gov Identifier (NCT) | Date and Status | Study | Procedure | Patients Age | Follow-Up | Primary Outcomes |
|---|---|---|---|---|---|---|
| NCT01301664 | 2013–2016 Completed | Cartilage Tissue Engineering | Harvested human cartilage tissues from osteoarthritic patient during total knee arthroplasty surgery | 30–70 years | n.d. | n.d. |
| NCT01791062 | 2013–2016 Completed | Safety and Efficacy Study of HYTOP® in the Treatment of Focal Chondral Defects | Focal chondral defect in femoro-tibial compartment of the knee joint | 18–50 years | 12 weeks | Adverse events with causal relationship to the investigational medical device evaluated with respect to type, incidence, and intensity up to study termination of each subject |
| NCT01879046 | 2013–2017 Completed | Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells | Total Knee arthroplasty | ≥18 years | 3 years | Increased expression of chondrogenic markers |
| NCT01813188 | 2013–2017 Completed (Phase 2) | Use of bone marrow mononuclear cells seeded onto a porous matrix of tricalcium phosphate ceramic and demineralized bone matrix, for the consolidation of tibial bone defects (pseudoarthrosis) | Autologous bone graft | 18–75 years | 6 months | Time needed to repair the focus of necrosis measured by pain radiography |
| NCT02033226 | 2014–2015 Completed (Phase 3) | Evaluation of Clinical, Anti-Inflammatory, and Anti-Infective Properties of Amniotic Membranes Used for Guided Tissue Regeneration in Contained Defects | Chronic Periodontitis | 30–55 years | 6 months | The mean difference in levels of hBD-2/IL-1β |
| NCT01362413 | 2014–2015 Completed | Validation of Laboratory Test for Predicting Bone Tissue Regeneration (Rebone-test) | Nonunion of Fracture (Pseudarthrosis) | ≥ 18 years | 12 months | Correlation between laboratory results at the surgery and clinical and radiographic results at 12 months, when patients will be considered as healed or not healed |
| NCT02409628 | 2015–2017 Completed | EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds | Application of the EktoTherix scaffold to a fresh wound created by the surgical removal of non-melanoma skin cancers | ≥18 years | 3 months | Incidence of device related adverse events |
| NCT02513368 | 2015 Completed (Phase 2) | Peri Implant Soft Tissue Healing in Single Implant Restoration Using Two Different Techniques | Augmentation procedure with Bio-Oss® and Bio-Gide® | 18–75 years | 1 year and 1 month | Change from baseline in the clinical characteristics of the peri implant mucosa |
| NCT00900718 | 2016 Completed | Comparison of Straumann Bone Ceramic and Bio-Oss With Guided Tissue Regeneration for Alveolar Ridge Preservation | Bone augmentation, after tooth extraction | 18–75 years | 32 weeks | The changes of bone level between baseline and 32-weeks post-extraction |
| NCT02859025 | 2016 Completed (Phase 1) | Concomitant Use of Buccal Fat Pad Derived Cells and Autogenous Bone in Alveolar Cleft Osteoplasty | Cleft of Alveolar Ridge | Child, adult and older adult | 6 months | Change in bone volume |
| NCT03113747 | 2017 Completed (Phase 1–2) | Allogeneic Adipose derived stem cells (ADSCs) and Platelet-Poor Plasma Fibrin Hydrogel to Treat Patients with Burn Wounds | Application over perforated autologous skin graft following the covering with hypoadhesive bandage | 18–65 years | 1 month | The degree of healing of skin flap after autologous skin grafting |
| NCT03076138 | 2017-2019 Completed | Gene-activated Bone Substitute for Maxillofacial Bone Regeneration | Bone grafting with gene-activated matrix maxillofacial regeneration | 18–60 years | 6 months | Bone tissue formation in the field of gene-activated bone substitute implantation |
| NCT01605201 | 2018 Completed (Phase 1) | Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage (Nose2Knee) | Implantation of a graft in a degenerative lesion of articular cartilage of knee | 18–55 years | 24 months | Safety for the patient and stability of the graft |
| NCT02673905 | 2018 Recruiting | Clinical Trial for the Regeneration of Cartilage Lesions in the Knee (NosetoKnee2) | Articular cartilage lesions in the knee | 18–65 years | 24 months | Comparison of the efficacy of the two investigational medicinal products (IMPs) |
| NCT02145130 | 2018 Recruiting (Phase 1) | Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects | Transplantation of an autologous tissue-engineered dermal substitute | 1–70 years | 21 days | Assessment and reporting of local infection rate and graft take |
| NCT03613090 | 2019 Not yet recruiting (Phase 2) | Novel Collagen Scaffold versus Conventional Scaffold in Regeneration of Human Dental Pulp Tissue | FDA-approved collagen-hydroxyapatite material called Syn-Oss for regeneration of pulp tissue | ≥12 years | 15 months | Observation of: Radiodensity at apex at 1mm from root vertex; increase in dentin wall thickness; increase in root length, in mm, and Periradicular status |
| NCT02090140 | 2015–2020 Ongoing | Microfracture Versus ADSCs for the Treatment of Articular Cartilage Defects | Microfracture followed by the application of ADSCs to the defect site | 18–50 years | 6, 12, 24 months | Health Scores on the Knee injury and Osteoarthritis Outcome Score (KOOS) Questionnaire |
| NCT01765244 | 2013–2020 Ongoing (Phase I–II) | Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients with Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment | Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold | ≥18 years | 24 months | Adverse events (and serious adverse events) causally related to experimental treatment; implant status (integrity, detachment, and reabsorption); local, regional, or systemic infections related with the implant; induced corneal neovascularization |
| NCT03698721 | 2018–2026 Ongoing | Urothelium Tissue Engineering Using Biopsies from Transurethral Resection of Prostate | Transurethral Resection of Prostate | ≥18 years | 6, 12, 36 months | Histological analysis of biopsy |
| NCT03103295 | 2018 Ongoing (Phase 1–2) | 3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects | Tissue-engineered bone-like construct transplantation | 18–60 years | 12, 36 months | Radiographic and MRI assessment in progression |
Note: n.d.: not defined; ADSCs: adipose-derived stem cells.